ClinicalTrials.gg
RecruitingNCT07814196iACTforDGBIUpdated Oct 23, 2026

Efficacy, and Cost-effectiveness of an Online ACT Intervention for Disorders of Gut-Brain Interaction (iACTforDGBI)

An interventional study of iACTforDGBI intervention and DGBI School in Disorders of Gut-brain Interaction and Distress, Psychological, sponsored by Örebro University, Sweden. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Örebro University, Sweden · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 23, 2026Now RecruitingFirst site in Sweden+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Test of efficacy and cost-effectiveness of the iACTforDGBI intervention vs an active control group (DGBI School)

02

Conditions studied

  • Disorders of Gut-brain Interaction
  • Distress, Psychological
03

In context

Lead sponsor

Örebro University, Sweden is the lead sponsor of 86 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years
  • Meeting clinical symptom levels for least one DGBI diagnosis (assessed with the Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults (Palsson et al., 2016))
  • Stable medication for psychiatric symptoms including anxiety, depression and sleep problems for at least two months prior to intervention.
  • Ability to read and write Swedish
  • Have access to a device (like computer, tablet or smartphone with) with access to the internet and that can be used to attend video conferences and preview the intervention platform (i.e., have a microphone and speakers or headphones).

Exclusion criteria

Exclusion Criteria:

  • Currently undergoing any form of psychological intervention.
  • Increased risk of suicide (≥4 points on MADRS item 9).
  • Ongoing or previously diagnosed severe psychiatric disorder, such as schizophrenia spectrum disorders or bipolar disorder.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    iACTforDGBI intervention

    ACT, mindfulness, and compassion-based online intervention

    Behavioral: iACTforDGBI intervention

  • Active comparator
    DGBI School

    Education on DGBI

    Other: DGBI School

Interventions

  • BehavioraliACTforDGBI intervention

    Online ACT, mindfulness, and compassion-based intervention, 8 sessions

  • OtherDGBI School

    Education on DGBI, diet, and psychological factors

06

What researchers measure

Primary outcomes

  1. Depressive symptoms (Patient Health Questionnaire-9, PHQ-9)

    Depressive symptoms measured with the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report scale. Each item is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 27. Higher scores indicate more severe depressive symptoms (worse outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  2. Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale, GSRS)

    Gastrointestinal symptom severity measured with the Gastrointestinal Symptom Rating Scale (GSRS), a 15-item self-report scale. Each item is rated on a 7-point Likert scale from 1 (no discomfort) to 7 (very severe discomfort), and items are summed. Total score ranges from 15 to 105. Higher scores indicate more severe gastrointestinal symptoms (worse outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  3. Anxiety symptoms (Generalized Anxiety Disorder 7-item scale, GAD-7)

    Anxiety symptoms measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Each of the 7 items is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 21. Higher scores indicate more severe anxiety symptoms (worse outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

Secondary outcomes

  1. Health-related quality of life (EuroQol 5-Dimension 5-Level, EQ-5D-5L)

    Health-related quality of life measured with the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). Five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each with five severity levels, are converted into a single index value using the \[Swedish c-TTO value set (Sun et al., 2022) / Swedish experience-based value set (Burström et al., 2020)\]. The index is anchored at 1.00 (full health) and 0.00 (a state equivalent to dead), with negative values representing states considered worse than dead; the \[Swedish c-TTO value set ranges from -0.31 to 1.00 / Swedish experience-based value set ranges from 0.243 to 0.976\]. Higher index values indicate better health-related quality of life (better outcome). The accompanying EQ visual analogue scale ranges from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better self-rated health.

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  2. Health-related quality of life (Assessment of Quality of Life-8 Dimensions, AQoL-8D)

    Health-related quality of life measured with the Assessment of Quality of Life-8 Dimensions (AQoL-8D), a 35-item instrument covering eight dimensions (independent living, happiness, mental health, coping, relationships, self-worth, pain, senses). Item responses are converted into a single utility score using the Australian scoring algorithm, on a scale anchored at 1.00 (full health) and 0.00 (dead); the algorithmic range is 0.09 to 1.00. Higher scores indicate better health-related quality of life (better outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  3. Health care use and productivity costs (Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness, TiC-P)

    Health care utilisation and productivity losses measured with the Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness (TiC-P). The TiC-P is not scored as a rating scale: reported numbers of health care contacts and days of absenteeism and reduced productivity are multiplied by Swedish unit costs to yield costs in SEK. The minimum is 0 SEK and there is no fixed maximum. Higher values indicate greater resource use and productivity loss (worse outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  4. Illness-related shame (Chronic Illness-related Shame Scale, CISS)

    Illness-related shame measured with the Chronic Illness-related Shame Scale (CISS), a 7-item unidimensional self-report scale. Each item is rated from 0 (never true) to 4 (always true) and items are summed. Total score ranges from 0 to 28. Higher scores indicate greater illness-related shame (worse outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  5. Psychological flexibility and inflexibility (Multidimensional Psychological Flexibility Inventory, MPFI)

    Items are rated on a 6-point scale from 1 (never true) to 6 (always true). Global psychological flexibility and global psychological inflexibility composite scores are each calculated as the mean of their constituent items, giving a score range of 1 to 6 for each composite. Higher psychological flexibility scores indicate greater flexibility (better outcome); higher psychological inflexibility scores indicate greater inflexibility (worse outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  6. Self-compassion (Self-Compassion Scale-Short Form, SCS-SF)

    Self-compassion measured with the Self-Compassion Scale-Short Form (SCS-SF), a 12-item self-report scale. Items are rated from 1 (almost never) to 5 (almost always); negatively worded items are reverse-scored and the total score is the mean of all items, ranging from 1 to 5. Higher scores indicate greater self-compassion (better outcome).

    Time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  7. Treatment credibility and expectancy (Credibility/Expectancy Questionnaire, CEQ)

    Treatment credibility and outcome expectancy measured with the Credibility/Expectancy Questionnaire (CEQ), a 6-item self-report measure. The credibility subscale (items 1-3) is rated from 1 (not at all) to 9 (very much) and summed, giving a range of 3 to 27. The expectancy subscale (items 4-6) combines one item rated from 1 to 9 and two items rated from 0% to 100%; these items are standardised and summed, so the subscale has no fixed raw minimum and maximum. Higher scores on both subscales indicate greater perceived treatment credibility and more positive outcome expectancy.

    Time frame: Week 0 (only expectancy sub scale), Week 4 (both subscales)

  8. System usability (System Usability Scale, SUS)

    Perceived usability of the online intervention platform measured with the System Usability Scale (SUS), a 10-item self-report scale. Items are rated from 1 (strongly disagree) to 5 (strongly agree); item scores are converted (odd-numbered items: response minus 1; even-numbered items: 5 minus response), summed and multiplied by 2.5. Total score ranges from 0 to 100. Higher scores indicate better perceived usability (better outcome).

    Time frame: Week 8

  9. Negative effects of treatment (Negative Effects Questionnaire, 20-item version, NEQ-20)

    Negative effects of treatment measured with the 20-item version of the Negative Effects Questionnaire (NEQ-20). For each item, participants indicate whether the negative effect occurred and, if so, rate its impact from 0 (not at all) to 4 (extremely) and attribute it either to the treatment or to other circumstances. The total score is the sum of the 20 items, ranging from 0 to 80. Higher scores indicate more frequent and more severe negative effects (worse outcome).

    Time frame: Week 8

  10. Global impression of change (Patient Global Impression of Change, PGIC)

    Participants' overall impression of change since starting the intervention (Week 0), measured with a single global change item rated on a 7-point scale from 0 (very much worse) to 6 (very much improved)\]. A higher score indicates greater perceived improvement (better outcome).

    Time frame: Week 4, Week 8, 3 months follow-up, 6 months follow-up

  11. Awareness of Processes Post-Intervention Scale

    Participants' awareness of the therapeutic processes targeted by the intervention, measured with the Awareness of Processes Post-Intervention Scale, a study-specific \[N\]-item self-report measure. Each item is rated from 1 (not at all true) to 5 (very much true) and items are summed, giving a total score range of 9 to 45. Higher scores indicate greater awareness of the targeted processes.

    Time frame: Week 8

Other outcomes

  1. Major Life Events Questionnaire

    Major life events and self-reported new psychological or physical diagnoses over the preceding 12 months, measured with the Major Life Events Questionnaire, a 28-item checklist. This is not scored as a rating scale; the outcome is the number of events endorsed, ranging from 0 to 28. A higher number indicates more major life events reported. This measure is used to characterise the sample and to identify potential confounders rather than as an efficacy outcome.

    Time frame: Week 0, 6 months follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 10, 2026
StartActual
Sep 15, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added — first site in Sweden
Show site
  • Örebro University · Örebro, Sweden
Oct 23, 2026
Design
Phase 2→Not applicable
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Sweden
    Show site
    • Örebro University · Örebro, Sweden
    Design Phase 2→Not applicable
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07814196
Lead sponsor
Örebro University, Sweden
Responsible party
Ines Trindade (Dr, Örebro University, Sweden) — Principal investigator
First posted
Sep 10, 2026
Start date
Sep 15, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion